IL233117A - Derivatives of dihydro-benzo-oxazine and dihydro-pyrido-oxazine - Google Patents

Derivatives of dihydro-benzo-oxazine and dihydro-pyrido-oxazine

Info

Publication number
IL233117A
IL233117A IL233117A IL23311714A IL233117A IL 233117 A IL233117 A IL 233117A IL 233117 A IL233117 A IL 233117A IL 23311714 A IL23311714 A IL 23311714A IL 233117 A IL233117 A IL 233117A
Authority
IL
Israel
Prior art keywords
dihydro
oxazine
pyrido
benzo
derivatives
Prior art date
Application number
IL233117A
Other languages
English (en)
Hebrew (he)
Other versions
IL233117A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL233117A0 publication Critical patent/IL233117A0/en
Publication of IL233117A publication Critical patent/IL233117A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL233117A 2011-12-22 2014-06-12 Derivatives of dihydro-benzo-oxazine and dihydro-pyrido-oxazine IL233117A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579231P 2011-12-22 2011-12-22
PCT/IB2012/057554 WO2013093849A1 (en) 2011-12-22 2012-12-20 Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Publications (2)

Publication Number Publication Date
IL233117A0 IL233117A0 (en) 2014-07-31
IL233117A true IL233117A (en) 2017-02-28

Family

ID=47678928

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233117A IL233117A (en) 2011-12-22 2014-06-12 Derivatives of dihydro-benzo-oxazine and dihydro-pyrido-oxazine

Country Status (42)

Country Link
US (2) US9539260B2 (cg-RX-API-DMAC7.html)
EP (1) EP2794600B1 (cg-RX-API-DMAC7.html)
JP (1) JP5903499B2 (cg-RX-API-DMAC7.html)
KR (1) KR101656592B1 (cg-RX-API-DMAC7.html)
CN (1) CN104011045B (cg-RX-API-DMAC7.html)
AP (1) AP4055A (cg-RX-API-DMAC7.html)
AR (1) AR089424A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012356083B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014015103B1 (cg-RX-API-DMAC7.html)
CA (1) CA2859764C (cg-RX-API-DMAC7.html)
CL (1) CL2014001452A1 (cg-RX-API-DMAC7.html)
CO (1) CO6990717A2 (cg-RX-API-DMAC7.html)
CR (2) CR20200286A (cg-RX-API-DMAC7.html)
CU (1) CU20140072A7 (cg-RX-API-DMAC7.html)
CY (1) CY1119939T1 (cg-RX-API-DMAC7.html)
DK (1) DK2794600T3 (cg-RX-API-DMAC7.html)
EA (1) EA025322B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14009999A (cg-RX-API-DMAC7.html)
ES (1) ES2661864T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400131A (cg-RX-API-DMAC7.html)
HR (1) HRP20180384T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036953T2 (cg-RX-API-DMAC7.html)
IL (1) IL233117A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04174A (cg-RX-API-DMAC7.html)
JO (1) JO3398B1 (cg-RX-API-DMAC7.html)
LT (1) LT2794600T (cg-RX-API-DMAC7.html)
MA (1) MA37142B1 (cg-RX-API-DMAC7.html)
MX (1) MX353342B (cg-RX-API-DMAC7.html)
MY (1) MY170922A (cg-RX-API-DMAC7.html)
NO (1) NO2809782T3 (cg-RX-API-DMAC7.html)
PE (1) PE20141598A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014501417B1 (cg-RX-API-DMAC7.html)
PL (1) PL2794600T3 (cg-RX-API-DMAC7.html)
PT (1) PT2794600T (cg-RX-API-DMAC7.html)
RS (1) RS56891B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201402237WA (cg-RX-API-DMAC7.html)
SI (1) SI2794600T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000210A1 (cg-RX-API-DMAC7.html)
TW (1) TWI577674B (cg-RX-API-DMAC7.html)
UA (1) UA112558C2 (cg-RX-API-DMAC7.html)
UY (1) UY34541A (cg-RX-API-DMAC7.html)
WO (1) WO2013093849A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2794600T1 (en) 2011-12-22 2018-03-30 Novartis Ag 2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6310474B2 (ja) * 2012-11-26 2018-04-11 ノバルティス アーゲー ジヒドロ−ピリド−オキサジン誘導体の固体形態
TW201422625A (zh) * 2012-11-26 2014-06-16 Novartis Ag 二氫-吡啶并-□衍生物之固體形式
CN105541698B (zh) * 2015-12-23 2018-07-10 滨海康杰化学有限公司 一种5-溴-2-三氟甲基吡啶的制备方法
GB2550437B (en) * 2016-05-20 2021-06-23 Bugworks Res Inc Heterocyclic compounds useful as anti-bacterial agents and method for production
IL275489B2 (en) * 2017-12-22 2024-06-01 Ravenna Pharmaceuticals Inc Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2020035424A1 (en) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
SG11202104243VA (en) 2018-12-06 2021-05-28 Daiichi Sankyo Co Ltd Cycloalkane-1,3-diamine derivative
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
PE20220565A1 (es) 2019-09-12 2022-04-13 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CN114728988B (zh) * 2019-11-20 2024-12-10 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的螺(异苯并呋喃氮杂环丁烷)化合物
KR20220155593A (ko) * 2020-03-19 2022-11-23 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물
EP4182322B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine derivatives as alk5 inhibitors
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
CN116535436B (zh) * 2023-05-06 2024-04-30 遵义医科大学 一种氟离子荧光探针及其合成方法和应用
WO2025099111A1 (en) * 2023-11-10 2025-05-15 Wella Germany Gmbh New telescoping syntheses of 6-hydroxy-benzomorpholine (3,4-dihydro-2h-1,4-benzoxazin-6-ol)

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
TW224941B (cg-RX-API-DMAC7.html) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9309716D0 (en) 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
HUP9900330A3 (en) 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN1145614C (zh) 1996-04-12 2004-04-14 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂,其制药用途及药物组合物
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
JP2002513445A (ja) 1996-09-06 2002-05-08 オブデュキャット、アクチボラグ 導電材料内の構造の異方性エッチング方法
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
KR100538095B1 (ko) 1996-11-18 2005-12-21 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식 억제제와 식물 위생제로서의 이들의 용도
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU758526B2 (en) 1998-02-25 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
EP1056728B1 (en) 1998-12-23 2007-11-21 Aventis Pharma Limited Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines
ATE318267T1 (de) 1999-09-30 2006-03-15 Neurogen Corp Einige alkylendiamin-substituierte heterocyclen
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1337527B1 (en) 2000-11-07 2009-10-14 Novartis AG Indolylmaleimide derivatives as protein kinase c inhibitors
JPWO2002072049A1 (ja) 2001-02-27 2004-07-02 山之内製薬株式会社 育毛用医薬組成物
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
MXPA05006133A (es) 2002-12-09 2006-03-09 Univ Texas Metodos para inhibir selectivamente la tirosino quinasa jano 3 (jak3).
CA2510851A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20050118708A (ko) 2003-04-03 2005-12-19 메르크 파텐트 게엠베하 혈전-색전 질환의 치료에서 응고 인자 xa의 저해제로서사용하기 위한피롤리디노-1,2-디카르복시-1-(페닐아미드)-2-(4-(3-옥소-모르폴리노-4-일)-페닐아미드) 유도체 및 관련화합물
JP2007527412A (ja) 2003-10-24 2007-09-27 エグゼリクシス, インコーポレイテッド Taoキナーゼモジュレーターおよび使用方法
JP5283336B2 (ja) 2004-01-12 2013-09-04 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド 選択的キナーゼ阻害剤
CN1984906A (zh) 2004-07-15 2007-06-20 日本烟草产业株式会社 稠合苯甲酰胺化合物和香草素受体1(vr1)活性抑制剂
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
EP1807075A2 (en) 2004-10-12 2007-07-18 Applied Research Systems ARS Holding N.V. Pi3 kinase gamma inhibitors for the treatment of anaemia
WO2006050054A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ZA200802080B (en) * 2005-09-07 2009-09-30 Serono Lab P13K inhibitors for the treatment of endometriosis
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
ATE510840T1 (de) 2006-06-26 2011-06-15 Ucb Pharma Sa Kondensierte thiazol-derivate als kinasehemmer
GB0620059D0 (en) 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
US7981893B2 (en) 2006-10-19 2011-07-19 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
KR20090108124A (ko) 2007-02-06 2009-10-14 노파르티스 아게 Pi 3-키나제 억제제 및 그의 사용 방법
MX2009009540A (es) 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US20110263569A1 (en) 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
WO2009071895A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009157196A1 (ja) 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
WO2010027002A1 (ja) 2008-09-05 2010-03-11 塩野義製薬株式会社 Pi3k阻害活性を有する縮環モルホリン誘導体
WO2010068881A1 (en) 2008-12-12 2010-06-17 Forest Laboratories Holdings Limited Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
US8669249B2 (en) 2009-03-27 2014-03-11 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
EP2445902A2 (en) 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
US8497265B2 (en) 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
US20140066431A1 (en) 2010-11-15 2014-03-06 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
US20140080810A1 (en) 2010-11-15 2014-03-20 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
CN102731525A (zh) 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 苯并吗啉衍生物
SI2794600T1 (en) 2011-12-22 2018-03-30 Novartis Ag 2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫-吡啶并-□衍生物之固體形式

Also Published As

Publication number Publication date
EP2794600B1 (en) 2017-12-06
UA112558C2 (uk) 2016-09-26
IL233117A0 (en) 2014-07-31
MY170922A (en) 2019-09-18
CL2014001452A1 (es) 2014-10-24
PL2794600T3 (pl) 2018-06-29
ECSP14009999A (es) 2018-10-31
CY1119939T1 (el) 2018-12-12
CR20140294A (es) 2014-08-13
LT2794600T (lt) 2018-02-26
JP2015506344A (ja) 2015-03-02
US9539260B2 (en) 2017-01-10
RS56891B1 (sr) 2018-04-30
US9763952B2 (en) 2017-09-19
JO3398B1 (ar) 2019-10-20
CO6990717A2 (es) 2014-07-10
AR089424A1 (es) 2014-08-20
SI2794600T1 (en) 2018-03-30
BR112014015103A2 (pt) 2020-10-27
CN104011045B (zh) 2016-08-24
MX2014007687A (es) 2014-07-30
US20130165436A1 (en) 2013-06-27
TW201333000A (zh) 2013-08-16
CA2859764C (en) 2019-12-31
HRP20180384T1 (hr) 2018-04-06
WO2013093849A1 (en) 2013-06-27
PH12014501417A1 (en) 2014-09-22
MA37142B1 (fr) 2019-07-31
CN104011045A (zh) 2014-08-27
AP4055A (en) 2017-03-07
KR20140107500A (ko) 2014-09-04
PT2794600T (pt) 2018-03-13
KR101656592B1 (ko) 2016-09-23
NZ624872A (en) 2015-07-31
HUE036953T2 (hu) 2018-08-28
UY34541A (es) 2013-09-02
JP5903499B2 (ja) 2016-04-13
MA37142A2 (fr) 2016-07-29
CR20200286A (es) 2020-09-23
TWI577674B (zh) 2017-04-11
EP2794600A1 (en) 2014-10-29
IN2014CN04174A (cg-RX-API-DMAC7.html) 2015-09-04
SG11201402237WA (en) 2014-09-26
PH12014501417B1 (en) 2014-09-22
AP2014007658A0 (en) 2014-05-31
EA201491247A1 (ru) 2014-09-30
EA025322B1 (ru) 2016-12-30
TN2014000210A1 (en) 2015-09-30
GT201400131A (es) 2015-06-02
US20160106753A1 (en) 2016-04-21
CA2859764A1 (en) 2013-06-27
MX353342B (es) 2018-01-08
ES2661864T3 (es) 2018-04-04
AU2012356083B2 (en) 2015-01-22
DK2794600T3 (en) 2018-03-12
NO2809782T3 (cg-RX-API-DMAC7.html) 2018-01-20
AU2012356083A1 (en) 2014-06-26
PE20141598A1 (es) 2014-11-14
BR112014015103B1 (pt) 2022-06-28
CU20140072A7 (es) 2014-10-02
MA37142A3 (fr) 2018-05-31

Similar Documents

Publication Publication Date Title
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL233051B (en) Anti-phf-tau antibodies and uses thereof
SG10201601802YA (en) Dispiropyrrolidine derivatives
PL2686331T3 (pl) Rebaudiozyd b i pochodne
EP2736330A4 (en) COMPOUNDS AND METHODS
ZA201401884B (en) New dihydroquinoline-2-one derivatives
EP2747560A4 (en) CONNECTIONS AND METHODS
IL229844B (en) Anti-psgl-1 antibodies and their use
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2736329A4 (en) COMPOUNDS AND METHODS
SG11201401937YA (en) New aryl-quinoline derivatives
IL247639B (en) History of heteroaryl piperidine
GB201110783D0 (en) Methods and uses
GB201116774D0 (en) Uses and methods
EP2716359A4 (en) COMPLEX AND USES THEREOF
GB201111775D0 (en) Compounds and uses thereof
SI2766342T1 (sl) Derivati fenil-gvanidina
GB201108490D0 (en) Methods and uses
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai
GB201119443D0 (en) GoWinging Concept and patent
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201114855D0 (en) Compounds and their issues

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed